About Neurocrine Biosciences, Inc.
https://www.neurocrine.comNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.
CEO
Kyle W. Gano
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 510
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Stifel
Buy
TD Cowen
Buy
Truist Securities
Buy
Citigroup
Buy
Canaccord Genuity
Buy
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:14.19M
Value:$1.92B
BLACKROCK, INC.
Shares:12.71M
Value:$1.72B
VANGUARD GROUP INC
Shares:9.71M
Value:$1.31B
Summary
Showing Top 3 of 819
About Neurocrine Biosciences, Inc.
https://www.neurocrine.comNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $794.9M ▲ | $541.9M ▲ | $209.5M ▲ | 26.36% ▲ | $2.11 ▲ | $299.5M ▲ |
| Q2-2025 | $687.5M ▲ | $530.6M ▼ | $107.5M ▲ | 15.64% ▲ | $1.09 ▲ | $152.9M ▲ |
| Q1-2025 | $572.6M ▼ | $539.8M ▲ | $7.9M ▼ | 1.38% ▼ | $0.08 ▼ | $31.3M ▼ |
| Q4-2024 | $627.7M ▲ | $476.4M ▲ | $103.1M ▼ | 16.43% ▼ | $1.03 ▼ | $181.7M ▼ |
| Q3-2024 | $622.1M | $430.3M | $129.8M | 20.86% | $1.28 | $191.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.11B ▲ | $4.27B ▲ | $1.26B ▲ | $3B ▲ |
| Q2-2025 | $975.6M ▲ | $3.89B ▲ | $1.2B ▲ | $2.69B ▲ |
| Q1-2025 | $943.5M ▼ | $3.69B ▼ | $1.15B ▲ | $2.54B ▼ |
| Q4-2024 | $1.08B ▼ | $3.72B ▲ | $1.13B ▲ | $2.59B ▼ |
| Q3-2024 | $1.23B | $3.54B | $816.1M | $2.72B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $209.5M ▲ | $227.5M ▲ | $-196.7M ▼ | $45.6M ▲ | $76.2M ▲ | $214.3M ▲ |
| Q2-2025 | $107.5M ▲ | $102M ▲ | $-29M ▼ | $-3.3M ▲ | $69.9M ▲ | $89.5M ▲ |
| Q1-2025 | $7.9M ▼ | $64.8M ▼ | $14.2M ▲ | $-117.9M ▲ | $-38.9M ▲ | $54.1M ▼ |
| Q4-2024 | $103.1M ▼ | $242.5M ▲ | $-68.3M ▼ | $-290M ▼ | $-116.1M ▼ | $235.2M ▲ |
| Q3-2024 | $129.8M | $158M | $24.7M | $26.4M | $209.4M | $149.9M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Product | $620.00M ▲ | $560.00M ▼ | $680.00M ▲ | $790.00M ▲ |
CEO
Kyle W. Gano
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 510
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Stifel
Buy
TD Cowen
Buy
Truist Securities
Buy
Citigroup
Buy
Canaccord Genuity
Buy
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:14.19M
Value:$1.92B
BLACKROCK, INC.
Shares:12.71M
Value:$1.72B
VANGUARD GROUP INC
Shares:9.71M
Value:$1.31B
Summary
Showing Top 3 of 819